News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,457 Results
Type
Article (41322)
Company Profile (266)
Press Release (687852)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (204857)
Career Advice (2030)
Deals (35576)
Drug Delivery (128)
Drug Development (81532)
Employer Resources (173)
FDA (16495)
Job Trends (14979)
News (346839)
Policy (32760)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2594)
Accelerated approval (45)
Adcomms (26)
Allergies (169)
Alliances (49590)
ALS (206)
Alzheimer's disease (1772)
Antibody-drug conjugate (ADC) (432)
Approvals (16864)
Artificial intelligence (638)
Autoimmune disease (266)
Automation (52)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (219)
Biotechnology (176)
Bladder cancer (185)
Brain cancer (70)
Breast cancer (734)
Cancer (5702)
Cardiovascular disease (457)
Career advice (1721)
Career pathing (41)
CAR-T (318)
CDC (55)
Celiac Disease (3)
Cell therapy (856)
Cervical cancer (46)
Clinical research (70670)
Collaboration (2018)
Company closure (5)
Compensation (1359)
Complete response letters (77)
COVID-19 (2737)
CRISPR (105)
C-suite (1083)
Cystic fibrosis (150)
Data (7621)
Decentralized trials (3)
Denatured (27)
Depression (157)
Dermatology (80)
Diabetes (580)
Diagnostics (6898)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (310)
Drug pricing (199)
Drug shortages (31)
Duchenne muscular dystrophy (274)
Earnings (91587)
Editorial (64)
Employer branding (21)
Employer resources (152)
Events (119176)
Executive appointments (1066)
FDA (20129)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (34)
Funding (1689)
Gene editing (228)
Generative AI (54)
Gene therapy (693)
GLP-1 (1044)
Government (4720)
Grass and pollen (6)
Guidances (404)
Healthcare (18975)
HIV (77)
Huntington's disease (56)
IgA nephropathy (94)
Immunology and inflammation (283)
Immuno-oncology (89)
Indications (178)
Infectious disease (3072)
Inflammatory bowel disease (215)
Inflation Reduction Act (14)
Influenza (135)
Intellectual property (286)
Interviews (318)
IPO (16662)
IRA (50)
Job creations (3648)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (96)
Layoffs (560)
Leadership (37)
Legal (7956)
Liver cancer (99)
Longevity (32)
Lung cancer (753)
Lymphoma (423)
Machine learning (59)
Management (59)
Manufacturing (1010)
MASH (182)
Medical device (13908)
Medtech (14016)
Mergers & acquisitions (20144)
Metabolic disorders (1473)
mRNA (196)
Multiple sclerosis (186)
NASH (17)
Neurodegenerative disease (405)
Neuropsychiatric disorders (104)
Neuroscience (3254)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4528)
Now hiring (76)
Obesity (689)
Opinion (285)
Ovarian cancer (212)
Pain (248)
Pancreatic cancer (291)
Parkinson's disease (353)
Partnered (33)
Patents (585)
Patient recruitment (654)
Peanut (61)
People (59498)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22022)
Phase 2 (31129)
Phase 3 (23175)
Pipeline (8079)
Policy (309)
Postmarket research (2569)
Preclinical (9378)
Press Release (64)
Prostate cancer (292)
Psychedelics (53)
Radiopharmaceuticals (319)
Rare diseases (1041)
Real estate (5967)
Recruiting (70)
Regulatory (25295)
Reports (55)
Research institute (2412)
Resumes & cover letters (353)
Rett syndrome (36)
RNA editing (20)
RSV (88)
Schizophrenia (176)
Series A (284)
Series B (209)
Service/supplier (11)
Sickle cell disease (109)
Special edition (22)
Spinal muscular atrophy (165)
Sponsored (47)
Startups (3636)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1083)
Venture capital (105)
Weight loss (443)
Women's health (122)
Worklife (20)
Date
Today (227)
Last 7 days (871)
Last 30 days (3067)
Last 365 days (30274)
2026 (11068)
2025 (30173)
2024 (35213)
2023 (40075)
2022 (51174)
2021 (55709)
2020 (54085)
2019 (46540)
2018 (35019)
2017 (32107)
2016 (31480)
2015 (37554)
2014 (31342)
2013 (26366)
2012 (28585)
2011 (29271)
2010 (27344)
Location
Africa (740)
Alabama (91)
Alaska (7)
Arizona (344)
Arkansas (14)
Asia (39607)
Australia (6494)
California (12916)
Canada (3687)
China (1302)
Colorado (554)
Connecticut (560)
Delaware (394)
Europe (85786)
Florida (1937)
Georgia (415)
Hawaii (3)
Idaho (62)
Illinois (1031)
India (88)
Indiana (589)
Iowa (23)
Japan (517)
Kansas (130)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1555)
Massachusetts (9210)
Michigan (355)
Minnesota (700)
Mississippi (6)
Missouri (143)
Montana (33)
Nebraska (29)
Nevada (139)
New Hampshire (84)
New Jersey (3413)
New Mexico (28)
New York (3384)
North Carolina (1638)
North Dakota (8)
Northern California (6448)
Ohio (387)
Oklahoma (23)
Oregon (41)
Pennsylvania (2602)
Puerto Rico (28)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5092)
Tennessee (208)
Texas (2042)
United States (45635)
Utah (386)
Vermont (1)
Virginia (308)
Washington D.C. (80)
Washington State (1039)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
729,457 Results for "genmab inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Genmab A/S Share Capital Reduction
April 19, 2026
·
3 min read
Press Releases
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
April 14, 2026
·
3 min read
Press Releases
Capital Increase in Genmab as a Result of Employee Warrant Exercise - February 24, 2026
February 25, 2026
·
3 min read
Press Releases
Genmab Publishes 2025 Annual Report
February 17, 2026
·
9 min read
Press Releases
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
April 14, 2026
·
8 min read
Press Releases
Genmab to Participate in Upcoming March 2026 Investor Conferences
February 26, 2026
·
3 min read
Press Releases
Passing of Genmab A/S’ Annual General Meeting - March 19, 2026
March 19, 2026
·
4 min read
Press Releases
Genmab Announces Initiation of Share Buy-Back Program
February 18, 2026
·
4 min read
Lymphoma
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study
Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result “doesn’t waver our optimism” regarding the bispecific antibody’s ongoing frontline trial.
January 19, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Genmab Portfolio Prioritization Update
December 29, 2025
·
4 min read
1 of 72,946
Next
